Analysts’ Ideas of the Week
Gold-Copper Junior Surges 47% WoW, Plus Biotech and Gold Producer Updates
Published: April 14, 2025
Author: FRC Analysts
*This article and research coverage is paid for and commissioned by issuers. See the bottom of this article for other important disclosures, rating, and risk definitions.
In this edition, we analyze the performance of our top picks, including a gold-copper junior, whose shares rose 47% last week. We also highlight key updates from a biotech, and a junior gold producer under coverage.
- Gain insights into companies under coverage that experienced significant developments last week, along with our analysts’ commentary and actionable takeaways.
- FRC top picks and standout performers from the past week
Monument Mining Limited (MMY.V, MMTMF)
PR Title: Enters into another agreement to process ore at its Burnakura mill in Australia
Analyst Opinion: Positive – This is the second such agreement signed by MMY this month. The latest announcement relates to a collaboration with Odyssey Gold Limited (ASX: ODY | MCAP: A$13M) to potentially process ore from the Tuckanarra gold project at MMY’s Burnakura mill, located 40 km away. Tuckanarra is an 80:20 joint venture between Odyssey and MMY, with MMY holding a 20% free-carried interest until a production decision. This project hosts 407 Koz of gold, grading 2.45 g/t. Earlier this month, MMY announced a similar agreement with Great Boulder Resources (ASX: GBR | MCAP: A$55M) to potentially process ore from GBR’s Side Well gold project, located 48 km from the Burnakura mill. Although both Tuckanarra and Side Well are in the exploration/development stage, these preliminary agreements, if converted into definitive toll milling arrangements, could provide MMY with a faster and more cost-effective path to stable cash flows. We anticipate record revenue and production this year from the company’s flagship Selinsing gold mine in Malaysia.
Updates on Financials, Technology, Energy, and Special Situations Companies Under Coverage
NurExone Biologic Inc./TSXV: NRX
PR Title: Announces U.S. uplisting intention, and closes $2.3M private placement
FRC Opinion: Positive – We believe NRX is on track to enter phase one clinical trials within 12 months. Last month, the company completed a preclinical study to support its application for an Investigational New Drug (IND) designation, a necessary step before initiating human clinical trials, for its ExoPTEN treatment for acute spinal cord injury (SCI). ExoPTEN has received orphan drug designation from the U.S. FDA, and the European Medicines Agency (EMA). We note that there is currently no cure for SCI.
FRC Top Picks
Top Picks
The following table shows last week’s top five performers among our Top Picks. The top performer, Lumina Gold Corp. (TSXV: LUM), was up 47%. LUM owns an advanced-stage gold-copper project in Ecuador.
Disclaimer
The opinions expressed in this report are the true opinions of the analyst(s) about any companies and industries mentioned. Any “forward looking statements” are our best estimates and opinions based upon information that is publicly available and that we believe to be correct, but we have not independently verified with respect to truth or correctness. There is no guarantee that our forecasts will materialize. Actual results will likely vary. Certain companies may be covered by FRC under an issuer paid model. FRC or companies with related management, and Analysts, may hold shares/securities in some companies mentioned in this report. This creates a potential conflict of interest which readers should consider . Distribution procedure: our reports are distributed first to our web-based subscribers on the date shown on this report then made available to delayed access users through various other channels for a limited time. To subscribe for real-time access to research, visit https://www.researchfrc.com/plans for subscription options. This report contains “forward looking” statements. Forward-looking statements regarding the Company, industry, and/or stock’s performance inherently involve risks and uncertainties that could cause actual results to differ from such forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products/services in the marketplace; acceptance in the marketplace of the Company’s new product lines/services; competitive factors; new product/service introductions by others; technological changes; dependence on suppliers; systematic market risks and other risks discussed in the Company’s periodic report filings, including interim reports, annual reports, and annual information forms filed with the various securities regulators. By making these forward-looking statements, Fundamental Research Corp. and the analyst/author of this report undertakes no obligation to update these statements for revisions or changes after the date of this report. Fundamental Research Corp DOES NOT MAKE ANY WARRANTIES, EXPRESSED OR IMPLIED, AS TO RESULTS TO BE OBTAINED FROM USING THIS INFORMATION AND MAKES NO EXPRESS OR IMPLIED WARRANTIES OR FITNESS FOR A PARTICULAR USE. ANYONE USING THIS REPORT ASSUMES FULL RESPONSIBILITY FOR WHATEVER RESULTS THEY OBTAIN FROM WHATEVER USE THE INFORMATION WAS PUT TO. ALWAYS TALK TO YOUR FINANCIAL ADVISOR BEFORE YOU INVEST. WHETHER A STOCK SHOULD BE INCLUDED IN A PORTFOLIO DEPENDS ON ONE’S RISK TOLERANCE, OBJECTIVES, SITUATION, RETURN ON OTHER ASSETS, ETC. ONLY YOUR INVESTMENT ADVISOR WHO KNOWS YOUR UNIQUE CIRCUMSTANCES CAN MAKE A PROPER RECOMMENDATION AS TO THE MERIT OF ANY PARTICULAR SECURITY FOR INCLUSION IN YOUR PORTFOLIO. This REPORT is solely for informative purposes and is not a solicitation or an offer to buy or sell any security. It is not intended as being a complete description of the company, industry, securities or developments referred to in the material. Any forecasts contained in this report were independently prepared unless otherwise stated, and HAVE NOT BEEN endorsed by the Management of the company which is the subject of this report. Additional information is available upon request. THIS REPORT IS COPYRIGHT. YOU MAY NOT REDISTRIBUTE THIS REPORT WITHOUT OUR PERMISSION. Please give proper credit, including citing Fundamental Research Corp and/or the analyst, when quoting information from this report. The information contained in this report is intended to be viewed only in jurisdictions where it may be legally viewed and is not intended for use by any person or entity in any jurisdiction where such use would be contrary to local regulations or which would require any registration requirement within such jurisdiction.